Healthcare M&A in Asia Pacific: 2026 Dealmaker's Guide

Healthcare M&A in Asia Pacific is one of the region’s most active deal sectors. Structural demand fundamentals — aging populations in Japan, Korea, and Australia; rapid urban middle-class growth in India and Southeast Asia; healthcare system modernisation across Indonesia, Vietnam, and the Philippines — generate sustained acquisition interest from PE funds, strategic acquirers, and sovereign wealth funds.

Amafi provides deal origination and execution support for M&A advisors active in APAC healthcare transactions — target identification, buyer research, CIM preparation, and execution capacity for boutique and institutional advisory firms covering the sector.

---

APAC Healthcare M&A Market Overview

Asia Pacific healthcare M&A has maintained deal volume above pre-pandemic levels since 2022, supported by structural demand, favourable demographics, and rising healthcare expenditure across the region. According to Bain & Company’s Global Healthcare Private Equity and M&A Report, Asia Pacific accounted for approximately 15–18% of global healthcare PE deal value in 2024–2025, with deal count growing faster than in North America or Europe.

Key structural drivers:

• Demographic demand — Japan, Korea, and Australia face rapidly aging populations requiring expanded hospital, aged care, and diagnostics infrastructure. India’s middle class is driving formal healthcare adoption at significant scale.
• Fragmented supply — Private healthcare delivery in most APAC markets remains highly fragmented, creating roll-up opportunities for PE and strategic acquirers seeking regional platform scale.
• Digital health maturation — The cohort of healthtech businesses that achieved scale during the pandemic has reached a stage where strategic M&A interest is accelerating, from hospital groups acquiring adjacent technology to payers investing in prevention and monitoring.
• Government healthcare reform — Indonesia, Vietnam, and the Philippines are actively expanding public healthcare infrastructure while encouraging private sector participation, generating licensing and concession-related acquisition opportunities.

---

Key Sub-Sectors

Private Hospital Groups and Healthcare Networks

Private hospital ownership and healthcare network consolidation account for the largest deal values in APAC healthcare M&A. PE-backed roll-ups have been active across India (Manipal Hospitals, Aster DM Healthcare, Max Healthcare), Southeast Asia (IHH Healthcare’s continued regional expansion), and Australia (where successive PE ownership cycles have shaped the Healthscope, Ramsay, and Lumus Imaging assets).

Roll-up targets typically present as profitable single-facility or small-chain operators with strong local market position but limited capital to expand geographically. PE acquirers typically target EBITDA of AUD 5–15m (or local equivalent) for bolt-on acquisitions around an established platform.

Valuation benchmarks: 8–14x EBITDA for scaled platforms; 6–9x EBITDA for bolt-on targets.

For PE funds running systematic healthcare acquisition programmes, see PE Healthcare Acquisitions in Asia Pacific — covering acquisition strategies, EBITDA multiples by sub-sector, the buyer universe, and AI-assisted deal workflow.

Pharmaceutical and Biopharmaceutical

India is the largest APAC market for pharma M&A, with deals driven by domestic branded generics consolidation, API manufacturing scale, and cross-border inbound from global pharma and healthcare PE. Japan has a mature pharma M&A market shaped by patent cliffs, R&D portfolio rationalisation, and succession-driven mid-market transactions. Korea is increasingly active in pharma acquisitions across Southeast Asia and is a growing source of biopharma cross-border deal flow.

Valuation benchmarks: 5–10x EBITDA for generic and branded generics businesses; premium multiples for specialty therapeutic platform assets with protected pipeline.

Medical Devices and Diagnostics

Diagnostics and pathology consolidation has been a feature of APAC healthcare M&A for over a decade, particularly in Australia (where listed platforms including Sonic Healthcare and Australian Clinical Labs operate alongside private PE-owned networks). Radiology networks and point-of-care diagnostics have attracted PE interest across Southeast Asia.

Medical devices M&A in APAC concentrates in distribution consolidation (aggregating independent distributors into regional platforms) and manufacturing-adjacent acquisitions in lower-cost production markets including Malaysia, Vietnam, and Thailand.

Valuation benchmarks: 6–10x EBITDA for diagnostics and pathology networks; distribution businesses typically trade at lower multiples of 4–6x EBITDA.

Digital Health and Healthtech

Telehealth platforms, EMR/EHR providers, pharmacy-on-demand, and digital diagnostics businesses that scaled during 2020–2022 are now mature M&A candidates. Strategic acquirers — hospital groups acquiring adjacent technology, payers investing in prevention tools — are more active than PE at the growth stage, but at EBITDA-positive scale these assets attract PE interest comparable to mainstream SaaS acquisitions.

Valuation benchmarks: 3–6x ARR for high-growth digital health platforms; 6–10x EBITDA for scaled, profitable healthtech businesses.

Aged Care

Australia and Japan are the primary APAC markets for aged care M&A, driven by demographic necessity and government reimbursement reform. Australian aged care has experienced significant ownership turnover following the Royal Commission, with PE (including TPG, Bain Capital) active in the sector alongside strategic acquirers. Japan’s aged care sector generates succession-driven M&A as owner-operators approach retirement without internal succession capacity.

Valuation benchmarks: 6–10x EBITDA for institutional-quality platforms; distressed assets have traded well below these levels during periods of regulatory disruption.

---

Buyer Universe

Buyer category	Examples	Primary thesis
Global healthcare PE	KKR, Carlyle, Blackstone, TPG, Advent International	Platform build, regional consolidation
Regional strategic acquirers	IHH Healthcare, Ramsay Health Care, Apollo Hospitals, Fortis Healthcare, Raffles Medical	Geographic and vertical extension
Sovereign wealth / government-linked	Temasek, GIC, ADIA, Mubadala	Long-duration healthcare mandate
Japanese strategic acquirers	Mitsui, Sumitomo, EPS Holdings, M3 Inc	APAC healthcare presence, succession pipeline
Korean acquirers	Samsung Biologics adjacent entities, CHA Medical Group, Kakao Healthcare	Digital health, APAC platform expansion
Indian conglomerates and hospital groups	Manipal, Aster DM, Fortis, Max Healthcare	Domestic consolidation, APAC expansion
Asia-Pacific focused PE	PAG, MBK Partners, Affinity Equity Partners	Cross-sector APAC platform acquisitions

---

AI Workflow for Healthcare M&A

Healthcare M&A in APAC has specific workflow challenges that AI infrastructure addresses directly.

Target identification. APAC healthcare targets are drawn from a fragmented universe: private hospital licensing registries (Indonesia’s BKPM OSS, India’s NHA, Thailand’s FDA), professional body registries, corporate filing databases, and sector intelligence feeds. AI platforms aggregate these sources and screen against thesis criteria — facility type, bed count, revenue range, ownership structure, succession indicators — to produce qualified shortlists at a fraction of the manual research time.

Buyer matching. Mapping the right buyer universe for a healthcare asset requires cross-referencing PE healthcare fund mandates, strategic acquirer expansion programmes, and sovereign wealth healthcare allocations. AI buyer matching layers thesis data, deal history, and cross-border acquisition patterns to identify the highest-conviction principals for each specific asset.

Due diligence support. Healthcare diligence involves large volumes of regulatory, clinical, and contractual documentation. AI review tools reduce the time to extract key risk and compliance flags — regulatory inspection history, reimbursement contract terms, employment and credentialing documentation — while flagging anomalies for senior review.

CIM and pitchbook production. Structuring a healthcare business for sale requires sector-specific formatting: clinical metrics alongside financial data, regulatory compliance summaries, reimbursement contract analysis, and workforce and credentialing profiles. AI-assisted CIM production compresses the time from mandate confirmation to pitch-ready document. See how Bookbuild handles healthcare CIM workflow for boutique advisory firms.

“Healthcare is one of the hardest sectors to source proprietary deal flow in APAC, because the owner base is fragmented — thousands of individual practitioners, clinic operators, and small networks that have no formal process for thinking about M&A. AI origination changes that calculus significantly. You can map the entire private healthcare landscape in a given market and identify which operators are approaching succession or expansion decisions. That kind of coverage is not possible with traditional relationship-based origination alone.” — Daniel Bae, Founder & CEO, Amafi (USD $30B+ transaction experience)

---

Regulatory Framework by Market

Market	Key foreign investment rules	Healthcare-specific notes
Australia	FIRB approval for foreign acquisitions above threshold	Private hospital and aged care acquisitions subject to national interest test; Aged Care Quality and Safety Commission approval for ownership changes
India	FDI permitted in hospitals (100% Greenfield, 74% Brownfield); CCI clearance required for large transactions	Pharma MNC acquisitions subject to separate policy review; price-controlled drug exposure relevant for pharma targets
Indonesia	Positive Investment List: foreign ownership caps vary by facility type; OSS approval required	Hospital ownership by foreign entities restricted; specialist clinics and diagnostic laboratories have varying foreign ownership caps
Japan	FEFTA foreign investment notification for healthcare assets; hospital ownership effectively restricted to medical corporations	Succession M&A through industry intermediaries; foreign ownership of medical corporations structurally limited
Singapore	Generally open to foreign investment; MoH regulates public-private hospital licensing	No formal foreign ownership caps for private healthcare; Medisave reimbursement approval relevant for insured platform acquisitions
Philippines	FIA restrictions on certain healthcare facility types; PSE listing requirements for large platforms	Hospital ownership by foreign entities capped at 40% in most categories

---

Working with Amafi on Healthcare M&A

Amafi provides deal origination and execution support for M&A advisors and institutional buyers active in APAC healthcare transactions.

For advisors with healthcare mandates, Amafi delivers: target identification across APAC healthcare facility and company registries, pitchbook and CIM preparation, buyer research and list-building across PE and strategic acquirers, financial modelling support, and execution capacity for diligence operations.

For institutional buyers, Amafi provides: proprietary healthcare deal flow sourced through AI-augmented origination, market mapping across APAC healthcare sub-sectors, and execution support from target identification through advisor introduction.

Explore origination support · Execution support services · Work with Amafi as a partner advisor

Related: PE Roll-Up Strategy in Accounting: A Guide · PE Deal Sourcing Software 2026 · Deal Sourcing for Private Equity in APAC